Dijkgraaf, E M <br/><br/>
A phase I trial combining carboplatin/doxorubicin with tocilizumab, an anti-IL-6R monoclonal antibody, and interferon-α2b in patients with recurrent epithelial ovarian cancer.  [electronic resource] 

 -  Annals of oncology : official journal of the European Society for Medical Oncology  Oct 2015 
 - 2141-9 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1569-8041 
<br/><br/><label>Standard No.: </label>10.1093/annonc/mdv309  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adenocarcinoma, Clear Cell--blood<br/>Adenocarcinoma, Mucinous--blood<br/>Adult<br/>Aged<br/>Antibodies, Monoclonal, Humanized--administration & dosage<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Biomarkers, Tumor--blood<br/>CA-125 Antigen--blood<br/>Carboplatin--administration & dosage<br/>Cystadenocarcinoma, Serous--blood<br/>Dose-Response Relationship, Drug<br/>Doxorubicin--administration & dosage<br/>Endometrial Neoplasms--blood<br/>Enzyme-Linked Immunosorbent Assay<br/>Female<br/>Follow-Up Studies<br/>Humans<br/>Interferon alpha-2<br/>Interferon-alpha--administration & dosage<br/>Interferon-gamma--blood<br/>Interleukin-6--blood<br/>Middle Aged<br/>Neoplasm Invasiveness<br/>Neoplasm Recurrence, Local--blood<br/>Neoplasm Staging<br/>Ovarian Neoplasms--blood<br/>Polyethylene Glycols--administration & dosage<br/>Prognosis<br/>Receptors, Interleukin-6--antagonists & inhibitors<br/>Recombinant Proteins--administration & dosage